Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
3D Cell Culture Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 116 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 116 pages
- Published: 13-06-2019
Market Overview
The 3D cell culture market is witnessing a stable growth due to the factors, like huge investments by life science companies for R&D, development of automated large-scale cell culture systems, and rising need for organ transplantation. Lack of experienced and skilled professionals and budget restriction for small and medium-sized laboratories are factors constraining the growth of the 3D cell culture market. However, increasing focus on regenerative medicine and stem cell is acting as an opportunity in the future. The scaffold-based segment holds the largest market share in the global market. The use of hydrogels in the scaffold-based 3D cell culture is the key factor driving the scaffold-based segment, as they can be derived naturally from protein and ECM components (laminin, fibrin, hyaluronic acid, chitosan, etc.). These gels are also biocompatible.
Scope of the Report
This report analyzes and discusses the 3D cell culture market. The market has been segmented on the basis of technology, application, end user, and geography. Based on technology, the market has been segmented into extracellular matrices (scaffolds), bioreactors, gels, scaffold-free platforms, microchips, and other technologies. The market, based on application, has been divided into research, drug discovery, tissue engineering, clinical applications, stem cell biology, and other applications. Based on end user, the market has been segregated into research laboratories and institutes, biotechnology and pharmaceutical industries, hospitals and diagnostic centers, and others end users.
Key Market Trends
Drug Discovery Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period
Conventionally, drug discovery has been carried out using animal models. However, with the explosion of drug molecules synthesized/discovered in the past two decades, there has been a growth in high-throughput screening. Consequently, drug discovery has become a process that was time-resource intensive. Additionally, animal testing is subject to ethical controversies. Consequently, the demand for alternative methods for drug testing and drug discovery processes has gained momentum.
A specific application of 3D cell culture in drug discovery is organ-on-chips. These systems are being extensively employed by cancer therapeutic manufacturers for improving the benefit-risk balance by targeting precisely a particular cell type, a defined biomechanism, or a precise receptor. The current up-trend in cancer therapeutics’ research is likely to further spur the application of 3D cell cultures in drug discovery. Over the forecast period, much novel cancer therapeutics are expected to receive market approval, which is likely to, in turn, drive the growth of the 3D cell culture market.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall 3D cell culture market with the United States accounting as the major contributor to the market. The United States is focusing more on R&D and is currently spending a lot on it. This has resulted in increasing technological advancements in the country. Many American applicants feature among the main patent applicants for the 3D cell culture domain. American applicants tend to develop their technologies in the United States, as well as in Asia. In 2016, an international collaboration between the United States, the United Kingdom, and the Netherlands, cancer-research heavy-weights, aimed to grow 1,000 new cell lines for scientists to study. The project is also expected to use cutting-edge techniques to generate its models, which will include 3D cultures called organoids, and cells that have been reprogrammed to grow indefinitely in culture. ICTDCCS 2018, 20th International Conference on 3D Cell Culture Systems, was held in Boston (the United States) on April 23-24, 2018. These factors have augmented the US 3D cell culture market and it is expected to further increase in the future.
Competitive Landscape
The 3D cell culture market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as 3D Biomatrix, Reinnervate Ltd, 3D Biotek LLC, Becton, Dickinson and Company, and Sigma Aldrich Corporation, is in turn, increasing the overall competitive rivalry in the market. Product advancements and improvement in the 3D cell culture technology by the major players are increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Huge R&D Investment by Life Science Companies
4.3.2 Development of Automated Large-scale Cell Culture Systems
4.3.3 Rising Need for Organ Transplantation
4.3.4 Use of 3D Cell Culture Models as Alternative Tools for In Vivo Testing
4.3.5 Increasing Focus on Regenerative Medicine
4.4 Market Restraints
4.4.1 Lack of Experienced and Skilled Professionals
4.4.2 Budget Restriction for Small- and Medium-sized Laboratories
4.4.3 Lack of Consistency in 3D Cell Culture Products
4.4.4 Stringent Process Controls for Advanced Handling Capabilities
4.5 Industry Attractiveness- Porter’s Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Extracellular Matrices (Scafffolds)
5.1.2 Bioreactors
5.1.3 Gels
5.1.4 Scaffold-free Platforms
5.1.5 Microchips
5.1.6 Other Technologies
5.2 By Application
5.2.1 Research
5.2.2 Drug Discovery
5.2.3 Tissue Engineering
5.2.4 Clinical Applications
5.2.5 Stem Cell Biology
5.2.6 Other Applications
5.3 By End User
5.3.1 Research Laboratories and Institutes
5.3.2 Biotechnology and Pharmaceutical Companies
5.3.3 Hospitals and Diagnostic Centers
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 UK
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3D Biotek LLC
6.1.2 Becton Dickinson and Company
6.1.3 Sigma Aldrich Corporation
6.1.4 Corning Incorporated
6.1.5 Thermo Fisher Scientific
6.1.6 Global Cell Solutions Inc.
6.1.7 Nanofiber Solutions Incorporation
6.1.8 Insphero AG
6.1.9 Lonza Group
6.1.10 Nano 3D Biosciences
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Extracellular Matrices (Scafffolds)
Bioreactors
Gels
Scaffold-free Platforms
Microchips
Other Technologies
By Application
Research
Drug Discovery
Tissue Engineering
Clinical Applications
Stem Cell Biology
Other Applications
By End User
Research Laboratories and Institutes
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Other End Users
Geography
North America
US
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Acne Therapeutics Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 118 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the acne therapeutics market are increasing sedentary lifestyles and unhealthy lifestyles, the rise in disposable income of consumers, increasing awareness about upcoming trends in acne treatments, and high prevalence of acne, globally.
The diet and nutrient intake determine the overall health of an individual. The food that is high in refined carbohydrates increases insulin, which results in hormonal problems, promoting acne formation.
More than 90% of the world’s population is found to be affected by acne at some point in their life. In the United States, there are 60 million suffering from acne problems. This includes all grades of acne, from the mild, occasional breakout to more severe conditions. Of the 60 million, 20% have some form of acne bad enough that it results in scarring of the skin. Therefore, there is an increasing adoption of acne cure products, which helps in driving the overall market.
In addition, rapid economic growth has also led to a substantial increase in the disposable incomes of middle-class people. With this increasing income, people are ready to spend more on their facial looks. Thus, the market for acne therapeutics is projected to grow rapidly over the forecast period.
Scope of the Report
As per the scope of the report, acne is a chronic inflammatory skin disease commonly affecting the adolescent and adult populations. Abnormal hormone production is found to be the key causative factor. The increasing use of acne medications is being indicated for its treatment. These include several prescriptions and over-the-counter medicines, such as retinoids, isotretinoin, antibiotics, salicylic acid, benzoyl peroxide, and oral contraceptives, among others. However, the development of effective therapeutics, with lesser side effects and high potential in untapped markets, is expected to provide growth opportunities to the overall market.
Key Market Trends
Topical is the Segment Under Administration that is Expected to Grow the Fastest
The utilization rate of topical medications for acne treatment is high, owing to the high availability of these acne products, with a high success rate and lesser side effects. These agents are directly applied on the skin and need to be used continuously for longer periods of time, from several weeks to months, to get effective result. Therefore, the preference for topical treatment is more, as compared to the oral mode of therapeutic administration. These oral medications are recommended as systemic therapies, after topical treatments fail to evoke a response.
Asia-Pacific Holds the Fastest Growth and is Expected to follow the Same Trend over the Forecast Period
Asia and Pacific is expected to be the fastest-growing region, due to increasing sedentary lifestyles and unhealthy food habits. Prosperity and a faster pace of life have changed the Chinese eating habits. Eating too much with high amounts of fat and calories and exercising less have led to an increase in obesity and acne problems. However, Asia-Pacific is expected to register the highest CAGR, due to the increase in affordability, surge in healthcare expenditure, and rise in awareness about safe acne medication products.
Competitive Landscape
There are many players in the market coming up with new products for acne treatment. Allergan PLC, Valeant Pharmaceutical International Inc., Bayer AG, and Galderma (Nestle Skin Health) are some of the major players in the acne therapeutics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Sedentary Lifestyle and Unhealthy Food Habits
4.2.2 Rise in Disposable Income of Consumers
4.2.3 Increasing Awareness About Current and Upcoming Acne Treatments
4.2.4 High Global Acne Prevalence
4.3 Market Restraints
4.3.1 Safety Issues Regarding the Products
4.3.2 Entry of Generics in the Acne Treatment Drug Market
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Therapeutics
5.1.1.1 Retinoid
5.1.1.2 Antibiotics
5.1.1.3 Hormonal Agents, Combination Medications, Anti-inflammatory
5.1.1.4 Other Agents
5.1.2 Other Treatments
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Topical
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Cipher Pharmaceuticals
6.1.2 Glaxosmithkline PLC
6.1.3 Bayer AG
6.1.4 Teva Pharmaceuticals
6.1.5 Ranbaxy
6.1.6 Allergan
6.1.7 F. Hoffmann-la Roche Ltd
6.1.8 Nestle SA (Galderma)
6.1.9 Johnson & Johnson
6.1.10 Valeant Pharmaceuticals International Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment
Therapeutics
Retinoid
Antibiotics
Hormonal Agents, Combination Medications, Anti-inflammatory
Other Agents
Other Treatments
By Route of Administration
Oral
Topical
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Active Pharmaceutical Ingredients (API) Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 110 pages | Published: 24-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 110 pages
- Published: 24-06-2019
Market Overview
The global active pharmaceutical ingredients market was valued at USD 165.74 billion in 2018 and is estimated to reach USD 236.7 billion in 2024, witnessing a CAGR of 6.1%. Some of the key factors that are driving the market include the increasing prevalence of infectious diseases, cardiovascular conditions, and other chronic disorders. Apart from these diseases, genetic disorders are significantly driving the usage of biologicals and biosimilars, globally.
Biosimilars, in many instances, serve as low-cost options. They hold the potential to create a more sustainable healthcare system by making room for innovation so that more patients continue to receive the best possible care.
The active pharmaceutical ingredients (API) market has traditionally been dominated by drugs, such as anti-infectives and diabetes, cardiovascular, analgesics, and pain management drugs. However, as per the R&D trends, the demand is shifting toward the development of complex APIs used in novel formulations, targetting niche therapeutic areas.
A large number of drugs are in the pipeline to develop treatments for cancer, an autoimmune disorder, and metabolic diseases. Owing to the rising prevalence of cancer, several manufacturers are venturing into the development of highly potent APIs (HPAPI) and specialty APIs, in order to cater to the rising demand for these products.
Scope of the Report
Active pharmaceutical ingredient (API) is a part of any drug that produces its effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. They are produced using highly technological industrial processes, both during the R&D and the commercial production phase.
Key Market Trends
Cardiology is Expected to hold the Largest Market Share in the Application Category
The API market, by application, is dominated by the cardiology segment, due to the vast population using various CVD drugs. This segment is projected to witness a CAGR of 6.05% during the forecast period.
Coronary heart disease (CHD) is the most common type of cardiac disease, with a death toll of over 370,000 people, annually, in the United States alone. According to the American Heart Association (AHA), cardiovascular disease accounts for 17.3 million deaths per year. The Centre for Disease Control and Prevention states that about 610,000 people die of heart diseases in the United States every year, i.e., one in every four deaths can be attributed to cardiovascular diseases (CVDs).
Cholesterol reducers and blood pressure lowering drugs are the key drug classes under CVS. Cholesterol reducers, especially Statins, are driving the CVS segment, and have emerged as the most important family of drugs among the cholesterol and triglycerides reducers. Healthcare spending for hypertension was USD 23 to 26 billion in 2017, in the developed markets alone. Another USD 14 to 17 billion was spent in 2017 in the pharmerging markets. The high expenditure on the cardiovascular category highlights the rising demand for APIs in the same.
North America Dominates the Market and is expected to continue its dominance through the Forecast Period
North America currently dominates the market for active pharmaceutical ingredients and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increasing incidences of disease and rising aging population. The United States holds the majority of the market in the North American region. However, the majority of its API requirements are met through imports from the Asian Markets. The trade statistics suggest that nearly 75% to 80% of the APIs imported to the United States are from China and India, as these countries have well-established manufacturing facilities and an abundant talent pool serving the pharmaceutical sector.
The recent political and trade policies implemented by the US government to increase import duties and taxes are expected to drive operational costs and increase the pricing pressure on the manufacturers. The FDA has also increased the application fees for new drug approvals and has increased the number of periodic inspections conducted on various off-share contract manufacturing facilities to ensure the supply of high-quality products to the US market.
Competitive Landscape
The active pharmaceutical ingredients market is highly competitive, and consists of several major players; thus, indicating a fragmented market scenario. The API market has several manufacturers from China and India holding a dominant market position, due to their large manufacturing footprints. In Europe, Italy, Germany, and the United Kingdom are the key regions for API trade, due to the presence of a well-developed pharmaceutical and life sciences industry.
A majority of the APIs produced by reputed MNCs are used for captive production. However, few players have emerged as contract manufacturers with a diversified client base. Further, with increasing technological advancements and product innovation, mid-size and small-scale companies are increasing their market presence, by introducing new ingredients with competitive prices. Companies, like Teva, Pfizer, Aurobindo, Sun Pharmaceuticals, Novartis, Mylan, and Boehringer Ingelheim, hold substantial market shares in the active pharmaceutical ingredients market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders
4.2.2 Increasing Adoption of Biologicals and Biosimilars
4.2.3 Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drug Research
4.3 Market Restraints
4.3.1 Drug Price Control Policies Across Various Countries
4.3.2 High Competition Between the API Manufacturers
4.3.3 Stringent Regulations
4.4 Industry Attractiveness Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Business Mode
5.1.1 Captive API
5.1.2 Merchant API
5.2 By Synthesis Type
5.2.1 Synthetic
5.2.2 Biotech
5.3 By Type
5.3.1 Generic
5.3.2 Branded
5.4 By Application
5.4.1 Cardiology
5.4.2 Pulmonology
5.4.3 Oncology
5.4.4 Ophthalmology
5.4.5 Neurology
5.4.6 Orthopedic
5.4.7 Other Applications
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aurobindo Pharma
6.1.2 Teva Pharmaceutical Industries Ltd
6.1.3 Pfizer Inc.
6.1.4 Novartis AG
6.1.5 BASF SE
6.1.6 Boehringer Ingelheim GmbH
6.1.7 Dr. Reddy’s Laboratories Ltd
6.1.8 Lupin Ltd
6.1.9 Mylan NV
6.1.10 Sun Pharmaceutical Industries Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Business Mode
Captive API
Merchant API
By Synthesis Type
Synthetic
Biotech
By Type
Generic
Branded
By Application
Cardiology
Pulmonology
Oncology
Ophthalmology
Neurology
Orthopedic
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Acute Myeloid Leukemia Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 115 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 115 pages
- Published: 10-06-2019
Market Overview
The global acute myeloid leukemia market was valued at USD 701.6 million in 2018, and is estimated to be valued at USD 1,539.99 million in 2024, witnessing a CAGR of 14.0%. The key factors propelling the growth of this market are high Incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in R&D by the pharmaceutical companies.
The American Cancer Society’s estimates for leukemia in the United States, for 2019, indicates that approximately 61,780 new cases of leukemia and 22,840 deaths from leukemia are expected to occur in the country. Among them, the number of new cases of acute myeloid leukemia (AML) will be around 21,450, from which most of the population will be adults. In terms of mortality, the society has estimated that there will be around 10,920 deaths due to AML, in the country. This statistics shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impact the growth of the AML market in the United States.
In addition, the global rise in the incidence of AML, along with increased mortality due to the disease, is expected to create a huge demand for AML therapeutics, thus, augmenting the global AML market.
Scope of the Report
This report estimates the global acute myeloid leukemia market and includes a detailed analysis of cytarabine, anthracycline drugs, and daunomycin.
Acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body against infections caused by bacteria.
Key Market Trends
Cytarabine is Expected to hold its Highest Market Share in the Chemotherapy Segment
In the chemotherapy segment of the acute myeloid leukemia market, cytarabine is believed to have the largest market size and is expected to witness a CAGR of 14.3% during the forecast period.
Most of the times, surgery and radiation therapy in cancer patients remove, kill, or damage cancer cells in a certain area, but chemotherapy works throughout the whole body and gives better results. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body. On the contrary, surgery and radiation only attack or kill the tumor that is located in a specific part. Since cancer is the disease which, most of the times, spreads across the whole body in a short period of time, oncologists choose to perform chemotherapy for better results.
Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin’s lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations. The American Cancer Society had estimated around 21,380 new cases of acute myeloid leukemia (AML) and approximately 10,590 deaths from AML in the United States, in 2016.
According to this society, these statistics involve a large percentage of the adult population. The increasing number of AML patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of AML in the country is the prime factor responsible for the growth of the market in the country.
Competitive Landscape
The acute myeloid leukemia market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new techniques with good results. Companies, like Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, and Sanofi-Aventis (Genzyme Corporation), hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
4.2.3 Increasing Investments in R&D
4.3 Market Restraints
4.3.1 Stringent Regulations on Drugs
4.3.2 Complications Related to Chemotherapy
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Chemotherapy
5.1.1 Cytarabine
5.1.2 Anthracycline Drugs
5.1.2.1 Daunomycin
5.1.2.2 Idarubicin
5.1.2.3 Mitoxantrone
5.1.3 Alkylating Agents
5.1.4 Anti-metabolites
5.1.5 Tyrosine Kinase Inhibitors
5.1.5.1 Dasatinib (Sprycel)
5.1.5.2 Imatinib (Gleevec)
5.1.6 Hormonal Therapy
5.1.7 Other Chemotherapies
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Celegene Corporation
6.1.2 Novartis AG
6.1.3 Genmab AS
6.1.4 Eisai Co. Ltd
6.1.5 Sanofi-Aventis (Genzyme Corporation)
6.1.6 Teva Pharmaceutical (Cephalon Inc.)
6.1.7 Pfizer Inc.
6.1.8 Bristol-Myers Squibb Company
6.1.9 Sunesis Pharmaceuticals Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Chemotherapy
Cytarabine
Anthracycline Drugs
Daunomycin
Idarubicin
Mitoxantrone
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Dasatinib (Sprycel)
Imatinib (Gleevec)
Hormonal Therapy
Other Chemotherapies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Advanced Drug Delivery Systems Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 110 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 110 pages
- Published: 07-06-2019
Market Overview
The global advanced drug delivery systems market is expected to register a CAGR of 5% during the forecast period, 2019 to 2024. The factors that are driving this market include the development of new drugs and biologics, advancements in understanding human biology and diseases, and increased R&D spending.
The advanced drug delivery systems are more focused on the maintenance of bioavailability of drug as per patient requirement, as well as the rate of drug delivery. Genetic engineering led to the development of new strategies to deliver biotechnologically-derived protein, peptide drugs, and chemoimmunoconjugates. The advanced drugs and biologics have higher efficiency with a smaller dosage of the drug, and hence they have to be supported with advanced drug delivery systems to gain maximum efficacy from the drug. In addition to the drugs and biologics, the drug-eluting implants have the potential to provide uninterrupted treatment and reduction in drug dosage (hence lesser need for frequent dosing). The advanced sustained release systems help target intestinal infections and others.
The increasing disease burden across the world, the proven efficacy of controlled-release drug delivery systems in addressing a wide range of diseases, and the growing R&D trends by both the innovators and the generic players for advanced drug delivery systems, are propelling the growth of the market.
Scope of the Report
The concept of advanced drug delivery system is to increase the efficacy of drugs. Advanced drug delivery systems are adopted to increase the bioavailability of the drug, reduce adverse effects and side effects, and increase drug stability.
Key Market Trends
Oral Drug Delivery System Segment by Type to Hold the Highest CAGR
The oral drug delivery system segment of the global advanced drug delivery systems market is expected to record the highest CAGR over the forecast period.
Over the past decade, the oral controlled-release drug delivery system has received extensive attention, due to its flexibility, reduced dosing frequency, and better patient compliance. The aforementioned factor, in combination with a reasonable cost of oral controlled-release drug delivery system, has led to the ease of market penetration.
North America Dominates the Market and is Believed to Follow the Same Trend Over the Forecast Period
North America currently dominates the advanced drug delivery systems market and is expected to continue its stronghold for a few more years. The United States holds the largest share of this market in the North America region. Advancements in pharmacology and the increasing adoption of a novel drug delivery system are expected to drive the US drug delivery systems market during the forecast period.
Competitive Landscape
The advanced drug delivery systems market is moderately competitive. Some of the major players in this market are Boston Scientific Corporation, Baxter International, 3M, Abbott Laboratories, and GlaxoSmithKline PLC. Owing to the continuous technological advancements in the drug delivery system, there is a possibility of new entrants in the market in the coming future.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Development of New Drugs and Biologics
4.2.2 Advancements in Understanding Human Biology and Diseases
4.2.3 Increased R&D Spending
4.3 Market Restraints
4.3.1 Product Recalls of Advanced Drug Delivery Products
4.3.2 Challenges in Nanomedicine-based Drug Delivery
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Oral Drug Delivery System
5.1.2 Injection-based Drug Delivery System
5.1.3 Inhalation/Pulmonary Drug Delivery System
5.1.4 Transdermal Drug Delivery System
5.1.5 Trans mucosal Drug Delivery System
5.1.6 Carrier-based Drug Delivery System
5.1.7 Other Types
5.2 By Application
5.2.1 Cardiovascular Diseases
5.2.2 Oncology
5.2.3 Urology
5.2.4 Diabetes
5.2.5 CNS
5.2.6 Ophthalmology
5.2.7 Inflammatory Diseases
5.2.8 Infections
5.2.9 Other Applications
5.3 By Technology
5.3.1 Prodrug
5.3.2 Implants And Intrauterine Devices
5.3.3 Targeted Drug Delivery
5.3.4 Polymeric Drug Delivery
5.3.5 Other Technologies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 3M
6.1.2 Abbott Laboratories
6.1.3 Amgen Inc.
6.1.4 Astrazeneca
6.1.5 Baxter International
6.1.6 Bayer Healthcare
6.1.7 Boston Scientific Corporation
6.1.8 Glaxosmithkline PLC
6.1.9 Merck & Co.
6.1.10 Novartis AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Oral Drug Delivery System
Injection-based Drug Delivery System
Inhalation/Pulmonary Drug Delivery System
Transdermal Drug Delivery System
Trans mucosal Drug Delivery System
Carrier-based Drug Delivery System
Other Types
By Application
Cardiovascular Diseases
Oncology
Urology
Diabetes
CNS
Ophthalmology
Inflammatory Diseases
Infections
Other Applications
By Technology
Prodrug
Implants And Intrauterine Devices
Targeted Drug Delivery
Polymeric Drug Delivery
Other Technologies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Aesthetic Fillers Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: Global |
| 116 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- Global
- 116 pages
- Published: 07-06-2019
Market Overview
The growth of the aesthetic fillers market can be attributed to the increasing trend of using anti-aging treatments and the demand for a much younger lifestyle. The demand for the ever-expanding range of dermal fillers and the number of operations performed has boosted the growth of the market studied. Due to the growing demand for facial aesthetics, which have a high demand for a wide range of products that treat various areas and the increasing average expenditure per patient in clinics, the market studied is growing. However, the side effects associated with dermal fillers and other factors are hindering the growth of the market studied.
Scope of the Report
The scope of this report comprises of the products currently available in the market studied. These fillers are used for anti-aging factors and are also helpful in several areas of treatment, including acne scars, enhancement of the dorsal area of hand, and increasing the volume of facial areas. The scope of this report is limited to injectables used in the above-mentioned procedures.
Key Market Trends
Absorbable Aesthetic Filler Segment is expected to exhibit Fastest Growth Rate Over the Forecast Period
Wrinkles are the first visible signs of aging. A face marked by furrows appears tired and neglected. Wrinkles are like small fractures of the skin, and the the aim of a filler is to fill them. Dermal fillers, also known as injectable implants, soft tissue fillers, or wrinkle fillers, are medical device implants approved by the FDA, in order to help create a smoother and/or fuller appearance in the face, including nasolabial folds, cheeks, and lips and to increase the volume of the back of the hand.
The FDA has approved some dermal fillers for the restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV). Also, several absorbable dermal fillers are approved by FDA , for lip and cheek augmentation in patients over the age of 21 and for the correction of contour deficiencies, such as wrinkles and acne scars. Any dermal filler can cause short- or long-term side effects, permanent side effects, or a combination. However, most of these side effects occur shortly after the procedure and go away in less than two weeks. Due to factors, like FDA approval to various absorbable fillers, the market for the same is expected to grow over the forecast period.
North America captured the Largest Market Share and is expected to Retain its Dominance
North America dominated the overall aesthetic filler market with the United States accounting as the major contributor to the market. Recently, consumers, around the world are showing increasing interest toward their aesthetic appearance. Aesthetic fillers that contain hyaluronic acid, collagen, and polymers and particles are used to give the skin or feature a cosmetic boost. As per the data from the American Society of Plastic Surgeons, around 2.6 million procedures have been performed in the United States using soft tissue fillers in 2016, which was 2% higher than in 2015. The increase was attributed to the safe and effective minimally-invasive procedures and their lesser side-effects. As of 2016, about 30 aesthetic fillers are approved and possess HA license for sale in Canada. Hence, the above statistics and facts affirms that the market studied is expected grow in the forecast period.
Competitive Landscape
The market studied is highly fragmented, with the majority of the manufacturing operations in North American countries. The presence of a significant number of players in the market studied has an impact on the prices of products by firms, such as Allergan, Integra Lifesciences, Galderma Pharma SA, Teoxane, and Sinclair Pharma PLC, among others. The industry is witnessing a series of acquisitions and mergers.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Facial Aesthetics
4.2.2 Rising Acceptance of Tissue Fillers with Increasing Dermal Filler Surgeries
4.2.3 Growing Aging Population
4.3 Market Restraints
4.3.1 Side Effects Associated with Dermal Fillers
4.3.2 Negative Effects of Unregistered Practitioners
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product Type
5.1.1 Absorbable
5.1.2 Non-absorbable
5.2 Material Type
5.2.1 Hyaluronic Acid
5.2.2 Polymers and Particles
5.2.3 Collagen
5.3 Application
5.3.1 Facial Line Correction
5.3.2 Face Lift
5.3.3 Lip Treatment
5.3.4 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan
6.1.2 Galderma Pharma SA
6.1.3 Integra Lifesciences
6.1.4 Laboratoires Vivacy SAS
6.1.5 Merz Pharma
6.1.6 Sinclair Pharma
6.1.7 Suneva Medical Inc.
6.1.8 Teoxane
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Product Type
Absorbable
Non-absorbable
Material Type
Hyaluronic Acid
Polymers and Particles
Collagen
Application
Facial Line Correction
Face Lift
Lip Treatment
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America